Want to see FR:AELIS full AI Analyst Report?

Aelis Farma SA (AELIS) Price & Analysis

3 Followers

AELIS Stock Chart & Stats

€1.01

-€0.03(-2.67%)

At close: Jul 27 4:00 PM EDT

€1.01

-€0.03(-2.67%)

Day’s Range― - ―

52-Week Range€0.89 - €2.30

Previous CloseN/A

Volume8.49K

Average Volume (3M)17.85K

Market Cap

€12.34M

Enterprise Value€13.81

Total Cash (Recent Filing)€8.21M

Total Debt (Recent Filing)€6.60M

Price to Earnings (P/E)―

Beta0.48

Next Earnings

Apr 05, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.47

Shares Outstanding13,706,586

10 Day Avg. Volume16,828

30 Day Avg. Volume17,851

Financial Highlights & Ratios

PEG Ratio0.19

Price to Book (P/B)3.49

Price to Sales (P/S)7.43

P/FCF Ratio-2.88

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.17

Revenue Forecast (FY)€12.40M

Bulls Say, Bears Say

Bulls Say

Focused Therapeutic PlatformA focused small-molecule platform around endocannabinoid modulation gives Aelis Farma a defined scientific and development identity. Its lead program targets cannabis use disorder by reducing THC psychoactive effects while preserving normal signaling, supporting a differentiated therapeutic rationale.

Improved Operating Cash BurnOperating cash outflow improved materially in 2025 compared with 2024, indicating some progress in controlling the cash required to fund operations. Although cash generation remains negative, this reduction could extend operational flexibility if the improvement is sustained.

Moderate Absolute DebtAbsolute debt remains described as moderate in the latest periods, which is less burdensome than the balance sheets of more highly leveraged companies. This provides some financial flexibility, even though falling equity and continuing losses weaken the overall capital cushion.

Bears Say

Persistent Losses And Deeply Negative MarginsSustained losses and deeply negative margins show that the current revenue base does not support the operating cost structure. The deterioration from roughly -56% net margin in 2023 to about -309% in 2025 indicates weak earnings quality and limited evidence of near-term self-funded profitability.

Ongoing Cash BurnPersistent negative operating and free cash flow means Aelis Farma continues consuming cash to fund its activities rather than generating internal resources. The resulting reliance on external funding can constrain development plans and increase financing risk while programs remain early stage.

Shrinking Equity Capital CushionThe sharp decline in equity demonstrates that ongoing losses are eroding the capital base that supports the business. A weaker cushion increases the importance of future financing and creates dilution or recapitalization risk, particularly given the company’s continuing cash requirements.

Aelis Farma SA News

Aelis Farma Secures Key EMA Backing and Extends Cash Runway as CB1 Pipeline Advances

Aelis Farma SA ( ($FR:AELIS) ) has provided an update. In the first half of 2026, Aelis Farma...

5d ago

AELIS

Aelis Farma’s AEF0117 THC Interaction Trial Withdrawn: What Investors Should Know

Aelis Farma SA ($FR:AELIS) announced an update on their ongoing clinical study. The Phase 1 trial “A Double...

7M ago

AELIS

Aelis Farma Deepens AEF0217 Down Syndrome Program With New Patient‑Focused Study

Aelis Farma SA ($FR:AELIS) announced an update on their ongoing clinical study. The new study, “Qualitative Evaluation of...

7M ago

AELIS

Aelis Farma’s New Study: AEF0117’s Impact on THC Metabolism

Aelis Farma SA (($FR:AELIS)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled...

11M ago

AELIS

AELIS FAQ

What was Aelis Farma SA’s price range in the past 12 months?

Aelis Farma SA lowest stock price was €0.89 and its highest was €2.30 in the past 12 months.

What is Aelis Farma SA’s market cap?

Aelis Farma SA’s market cap is €12.34M.

When is Aelis Farma SA’s upcoming earnings report date?

Aelis Farma SA’s upcoming earnings report date is Apr 05, 2027 which is in 197 days.

How were Aelis Farma SA’s earnings last quarter?

Aelis Farma SA released its earnings results on Sep 15, 2026. The company reported -€0.176 earnings per share for the quarter.

Is Aelis Farma SA overvalued?

According to Wall Street analysts Aelis Farma SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Aelis Farma SA pay dividends?

Aelis Farma SA does not currently pay dividends.

What is Aelis Farma SA’s EPS estimate?

Aelis Farma SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Aelis Farma SA have?

Aelis Farma SA has 13,706,586 shares outstanding.

What happened to Aelis Farma SA’s price movement after its last earnings report?

Aelis Farma SA reported an EPS of -€0.176 in its last earnings report. Following the earnings report the stock price went up 1.053%.

Which hedge fund is a major shareholder of Aelis Farma SA?

Currently, no hedge funds are holding shares in FR:AELIS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Aelis Farma SA

Aelis Farma S.A., a French biotechnology company founded in 2013 and headquartered in Bordeaux, is dedicated to the discovery and development of treatments for brain-related illnesses. The firm's research pipeline primarily focuses on signaling-specific inhibitors that target CB1 receptors. Its leading investigational drug, AEF0117, is currently advancing through Phase 2b clinical trials, designed to alleviate the harmful impacts of excessive cannabis consumption. Furthermore, AEF0217, another key drug candidate, has successfully completed Phase 1 clinical trials, with the goal of addressing cognitive impairments linked to Down syndrome and other similar conditions.